Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Pooling Strategy Increases Efficiency and Reduces Cost of COVID-19 PCR Tests

By LabMedica International staff writers
Posted on 31 Aug 2020
A new way of manipulating samples for COVID-19 testing of asymptomatic and symptomatic individuals provides both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.

Recent reports have suggested that10-30% of SARS-CoV-2 (COVID-19) infected patients are asymptomatic and that significant viral shedding may occur prior to symptom onset. More...
Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. A major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, which is primarily performed on symptomatic patients, due to limited laboratory capabilities as well as limited access to genome-extraction and PCR (Polymerase Chain Reaction) reagents.

To break this bottleneck, investigators at Ben-Gurion University of the Negev (Beer Sheva, Israel) developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a large set of samples using a single round of testing.

In the P-BEST approach, each individual’s sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing designed for maximizing carrier detection. In the pilot study, the investigators pooled sets of 384 samples into 48 pools, which provided both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.

Results revealed that the P-BEST method successfully identified up to five positive carriers within sets of 384 samples. P-BEST could be configured based on the carrier rate of a given population. Thus, if the carrier rate was below 1.3%, the method provided both an eight-fold improvement in testing efficiency as well as an eight-fold reduction in test costs.

"Approximately 10-30% of COVID-19 infected patients are asymptomatic and significant viral spread can occur days before symptom onset," said contributing author Dr. Angel Porgador, deputy vice-president of research and development at Ben Gurion University of the Negev. "Until there is a vaccine, there will be an urgent need to increase diagnostic testing capabilities to allow for screening of asymptomatic and pre-symptomatic populations. This new single stage diagnostic test will help prevent the spread of the disease by identifying these patients sooner and at a lower cost using significantly fewer tests."

The P-BEST method was described in the August 21, 2020, online edition of the journal Science Advances.

Related Links:
Ben-Gurion University of the Negev


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.